Bladder Cancer

Nivolumab After Surgical Resection Improves Disease-Free Survival for Patients With High-Risk Muscle-Invasive Urothelial Carcinoma

Adjuvant therapy with the immune checkpoint inhibitor nivolumab following surgery improved disease-free survival in patients with high-risk...

Prostate Cancer

Adding Talazoparib to Enzalutamide Extends Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer

The addition of the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib to the androgen receptor signaling inhibitor enzalutamide...

Bladder Cancer

Single-Arm Phase II Noninferiority Trial Evaluates Active Surveillance vs Cystectomy Following Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Carcinoma

Researchers have found that following chemotherapy, 46% of patients with muscle-invasive urothelial carcinoma were able to avoid...

Prostate Cancer

TRITON3: Rucaparib vs Physician’s Choice of Single-Agent Therapy in Metastatic Castration-Resistant Prostate Cancer With BRCA or ATM Alterations

As reported in The New England Journal of Medicine by Karim Fizazi, MD, PhD, and colleagues, the phase III TRITON3 trial has shown significantly...

Kidney Cancer

Extended Follow-up Supports First-Line Use of Nivolumab Plus Cabozantinib in Advanced Renal Cell Carcinoma

The 3-year follow-up of the phase III CheckMate 9ER trial demonstrates superior outcomes with the combination of nivolumab plus...


Lung Cancer

Vamsidhar Velcheti, MD, on NSCLC: Sotorasib in KRAS-Mutated Disease


Study Examines Barriers to Survivorship Care

Even among a large group of cancer survivors who were mostly insured, college-educated, and had annual incomes above the national average, up to 10% delayed care in the previous 12 months because they simply could not afford out-of-pocket expenses like copays and deductibles. These findings were...


Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Solid Tumors

Carey K. Anders, MD, on Brain Metastases: Integrating Immunotherapy Into Clinical Care

Multiple Myeloma

APOLLO Trial: Addition of Subcutaneous Daratumumab to Pomalidomide/Dexamethasone in Previously Treated Patients With Multiple Myeloma

As reported in The Lancet Oncology by Meletios A. Dimopoulos, MD, and colleagues, the phase III APOLLO trial has shown significantly improved progression-free survival with the addition of subcutaneous daratumumab to pomalidomide/dexamethasone in patients with previously treated multiple myeloma....

Prostate Cancer

Novel PSMA-Targeted Radiotherapy Improves Radiographic Progression-Free and Overall Survival in Metastatic Prostate Cancer

Lutetium-177–PSMA-617 (Lu-177–PSMA-617)—an investigational radioligand therapy—significantly improved radiographic progression-free survival and overall survival when added to standard of care compared with standard of care alone for men with metastatic castration-resistant prostate cancer whose...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Breast Cancer

Massimo Cristofanilli, MD, on Breast Cancer: Updated Analysis on Palbociclib Plus Fulvestrant

Issues in Oncology

Organizations Issue Statement Encouraging Return to HPV Vaccination

Doctors and scientists across America at National Cancer Institute (NCI)-designated cancer centers and other organizations recently issued a joint statement urging the nation’s health-care systems, physicians, parents, children, and young adults to get human papillomavirus (HPV) vaccination back on ...


Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...